Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39
Matthew C. Hyman, Danica Petrovic-Djergovic, Scott H. Visovatti, Hui Liao, Sunitha Yanamadala, Diane Bouïs, Enming J. Su, Daniel A. Lawrence, M. Johan Broekman, Aaron J. Marcus, David J. Pinsky
Matthew C. Hyman, Danica Petrovic-Djergovic, Scott H. Visovatti, Hui Liao, Sunitha Yanamadala, Diane Bouïs, Enming J. Su, Daniel A. Lawrence, M. Johan Broekman, Aaron J. Marcus, David J. Pinsky
View: Text | PDF
Research Article Cardiology

Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39

  • Text
  • PDF
Abstract

Leukocyte and platelet accumulation at sites of cerebral ischemia exacerbate cerebral damage. The ectoenzyme CD39 on the plasmalemma of endothelial cells metabolizes ADP to suppress platelet accumulation in the ischemic brain. However, the role of leukocyte surface CD39 in regulating monocyte and neutrophil trafficking in this setting is not known. Here we have demonstrated in mice what we believe to be a novel mechanism by which CD39 on monocytes and neutrophils regulates their own sequestration into ischemic cerebral tissue, by catabolizing nucleotides released by injured cells, thereby inhibiting their chemotaxis, adhesion, and transmigration. Bone marrow reconstitution and provision of an apyrase, an enzyme that hydrolyzes nucleoside tri- and diphosphates, each normalized ischemic leukosequestration and cerebral infarction in CD39-deficient mice. Leukocytes purified from Cd39–/– mice had a markedly diminished capacity to phosphohydrolyze adenine nucleotides and regulate platelet reactivity, suggesting that leukocyte ectoapyrases modulate the ambient vascular nucleotide milieu. Dissipation of ATP by CD39 reduced P2X7 receptor stimulation and thereby suppressed baseline leukocyte αMβ2-integrin expression. As αMβ2-integrin blockade reversed the postischemic, inflammatory phenotype of Cd39–/– mice, these data suggest that phosphohydrolytic activity on the leukocyte surface suppresses cell-cell interactions that would otherwise promote thrombosis or inflammation. These studies indicate that CD39 on both endothelial cells and leukocytes reduces inflammatory cell trafficking and platelet reactivity, with a consequent reduction in tissue injury following cerebral ischemic challenge.

Authors

Matthew C. Hyman, Danica Petrovic-Djergovic, Scott H. Visovatti, Hui Liao, Sunitha Yanamadala, Diane Bouïs, Enming J. Su, Daniel A. Lawrence, M. Johan Broekman, Aaron J. Marcus, David J. Pinsky

×

Figure 4

CD39 deficiency does not impair bone marrow reconstitution.

Options: View larger image (or click on image) Download as PowerPoint
CD39 deficiency does not impair bone marrow reconstitution.
To determine...
To determine the contribution of donor and recipient cells to the neutrophil and monocyte subpopulations, we developed a quantitative PCR that measured neomycin gene dosage. (A) Mixtures of WT and Cd39–/– peripheral blood leukocytes (x axis indicates cell number × 10,000) were used to validate this assay. Leukocyte buffy coats from bone marrow–transplanted mice were sorted by flow cytometry to isolate the neutrophil and monocyte subpopulations. The neutrophils (B) and monocytes (C) were then quantified for relative neomycin DNA. Peripheral blood from untransplanted WT (green) and Cd39–/– (black) mice was separated into neutrophil (D) and monocyte (E) populations by flow cytometry and then examined for CD39 expression. Isotype control is shown in orange. Peripheral leukocytes from bone marrow chimeric mice were sorted into neutrophil (F) and monocyte (G) populations and stained for CD39: WT→WT (green), WT→KO (red), KO→WT (magenta), and KO→KO (black). Whole-lung homogenates from bone marrow chimeric mice were sorted for endothelial cells (H) and stained for CD39: WT→WT (green), WT→KO (red), KO→WT (magenta), and KO→KO (black). (I) Whole-lung digests from bone marrow–transplanted mice were analyzed for relative CD39 expression on endothelial, neutrophil, and macrophage subpopulations. n = 4 or 5 per group; *P < 0.001, **P < 0.01, ***P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts